Clinical Trial Update: Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating a high-dose icotinib regimen in patients with advanced non-small cell lung cancer after failure of prior targeted therapy; status of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Anhui Medical University | Conditions: NSCLC | Phase 2 | Status: UNKNOWN